BlackRock’s Werewolf Therapeutics HOWL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$84.6K Sell
101,608
-35
-0% -$24 ﹤0.01% 4996
2025
Q4
$64.4K Buy
101,643
+320
+0.3% +$389 ﹤0.01% 4997
2025
Q3
$200K Sell
101,323
-260,660
-72% -$357K ﹤0.01% 4681
2025
Q2
$395K Sell
361,983
-1,309,872
-78% -$1.35M ﹤0.01% 4502
2025
Q1
$1.63M Sell
1,671,855
-28,577
-2% -$37.4K ﹤0.01% 4054
2024
Q4
$2.52M Buy
1,700,432
+63,382
+4% +$129K ﹤0.01% 3972
2024
Q3
$3.47M Buy
1,637,050
+49,326
+3% +$112K ﹤0.01% 3838
2024
Q2
$3.87M Buy
1,587,724
+1,422,932
+863% +$6.83M ﹤0.01% 3780
2024
Q1
$1.07M Buy
164,792
+92,564
+128% +$539K ﹤0.01% 4184
2023
Q4
$279K Sell
72,228
-4,885
-6% -$12.5K ﹤0.01% 4558
2023
Q3
$165K Buy
77,113
+3,132
+4% +$8.63K ﹤0.01% 4727
2023
Q2
$226K Buy
73,981
+34,987
+90% +$98.5K ﹤0.01% 4703
2023
Q1
$101K Buy
38,994
+456
+1% +$1.36K ﹤0.01% 4950
2022
Q4
$79K Sell
38,538
-109,471
-74% -$286K ﹤0.01% 5110
2022
Q3
$668K Sell
148,009
-35,948
-20% -$195K ﹤0.01% 4629
2022
Q2
$752K Sell
183,957
-1,099,588
-86% -$5.02M ﹤0.01% 4649
2022
Q1
$5.65M Buy
1,283,545
+7,337
+0.6% +$51.4K ﹤0.01% 3892
2021
Q4
$15.2M Buy
1,276,208
+906,247
+245% +$13.7M ﹤0.01% 3432
2021
Q3
$6.35M Buy
369,961
+4,098
+1% +$69.9K ﹤0.01% 3865
2021
Q2
$6.38M Buy
+365,863
New +$5.01M ﹤0.01% 3799

Other funds holding HOWL

BlackRock's HOWL Position: Q1 2026 in Review

BlackRock reduced its Werewolf Therapeutics (HOWL) stake by 0.03% in Q1 2026, selling an estimated $24 and leaving 101,608 shares worth $84.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4996.

BlackRock first reported a position in HOWL in Q2 2021 and has held it in 20 quarters since. The position peaked at $15.2M in Q4 2021. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • BlackRock held 101,608 shares of Werewolf Therapeutics worth $84.6K as of Q1 2026.
  • BlackRock sold 35 Werewolf Therapeutics shares in Q1 2026, an estimated $24.
  • Werewolf Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4996 holding.
  • BlackRock first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • BlackRock's Werewolf Therapeutics position peaked at $15.2M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.